Vimarsana
Biggest News Aggregation in the World

Between Jan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Between Jan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Between Jan Today - Breaking & Trending Today

#VisualAbstract: Stereotactic body radiotherapy enhances survival in patients with non-small cell lung cancer - Vimarsana News

#VisualAbstract: Stereotactic body radiotherapy enhances survival in patients with non-small cell lung cancer

1. Median progression-free survival was greater in the SBRT group than in the standard-of-care group. 2. Patients with NSCLC displayed a significant survival benefit with SBRT in comparison to patients with breast cancer. Evidence Rating Level: 1 (Excellent) Study Rundown: Most patients with metastatic breast cancer develop resistance to systemic therapy. Stereotactic body radiotherapy (SBRT) is a

Stereotactic body radiotherapy enhances survival in patients with non-small cell lung cancer - Vimarsana News

Stereotactic body radiotherapy enhances survival in patients with non-small cell lung cancer

1. Median progression-free survival was greater in the SBRT group than in the standard-of-care group. 2. Patients with NSCLC displayed a significant survival benefit with SBRT in comparison to patients with breast cancer. Evidence Rating Level: 1 (Excellent) Study Rundown: Most patients with metastatic breast cancer develop resistance to systemic therapy. Stereotactic body radiotherapy (SBRT)

#VisualAbstract: Pembrolizumab and chemotherapy combination improves survival in advanced pleural mesothelioma - Vimarsana News

#VisualAbstract: Pembrolizumab and chemotherapy combination improves survival in advanced pleural mesothelioma

1. Patients in the pembrolizumab plus chemotherapy group reported a significantly greater overall survival compared to those in the chemotherapy alone group (17.3 months vs. 16.1 months). 2. Grade 5 adverse events were comparable in both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Pleural mesothelioma often presents at an advanced stage, and platinum–pemetrexed chemotherapy is a

Pembrolizumab and chemotherapy combination improves survival in advanced pleural mesothelioma - Vimarsana News

Pembrolizumab and chemotherapy combination improves survival in advanced pleural mesothelioma

1. Patients in the pembrolizumab plus chemotherapy group reported a significantly greater overall survival compared to those in the chemotherapy alone group (17.3 months vs. 16.1 months). 2. Grade 5 adverse events were comparable in both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Pleural mesothelioma often presents at an advanced stage, and platinum–pemetrexed chemotherapy

Discontinuing oxytocin during active labour has no significant impact on neonatal morbidity - Vimarsana News

Discontinuing oxytocin during active labour has no significant impact on neonatal morbidity

1. Neonatal morbidity rate was comparable between the continuous oxytocin and discontinuous oxytocin groups. 2. There was no significant difference in adverse events between both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Oxytocin is known for reducing labour duration but may pose risks for neonatal morbidity. In the multicenter STOPOXY trial, participants receiving oxytocin